Choreo LLC Has $1.44 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Choreo LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,403 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the quarter. Choreo LLC’s holdings in Alnylam Pharmaceuticals were worth $1,436,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SVB Wealth LLC bought a new stake in Alnylam Pharmaceuticals in the first quarter valued at $27,000. Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. Ameritas Advisory Services LLC bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $42,000. AlphaQuest LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $43,000. Finally, Parkside Financial Bank & Trust boosted its holdings in Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 44 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total value of $4,512,700.00. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,517,119.43. This represents a 13.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 78,328 shares of company stock worth $35,705,793. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent research reports. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Twenty-three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $451.27 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a 50-day moving average of $455.81 and a 200-day moving average of $396.74. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a market cap of $59.62 billion, a P/E ratio of -182.70 and a beta of 0.30.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.